Scarica l'app Stockscreener
59.19
3.05%
-1.86
Dopo l'orario di chiusura:
59.30
0.11
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$61.05
Aprire:
$61.21
Volume 24 ore:
10.63M
Relative Volume:
0.96
Capitalizzazione di mercato:
$120.11B
Reddito:
$48.30B
Utile/perdita netta:
$-8.95B
Rapporto P/E:
-13.39
EPS:
-4.42
Flusso di cassa netto:
$13.94B
1 W Prestazione:
-1.19%
1M Prestazione:
+1.68%
6M Prestazione:
+18.50%
1 anno Prestazione:
+13.28%
Intervallo 1D:
$59.18
$61.49
Intervallo di 1 settimana:
$59.18
$61.49
Portata 52W:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Confronta BMY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
59.19 | 120.11B | 48.30B | -8.95B | 13.94B | -4.42 |
|
LLY
Lilly Eli Co
|
852.35 | 765.56B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.34 | 355.44B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
73.60 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
87.87 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma
Bristol-Myers Squibb’s SWOT analysis: stock faces legacy challenges amid growth potential - Investing.com
Is Bristol-Myers Squibb (BMY) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Is Bristol-Myers Squibb (BMY) Among the Cheap Stocks to Buy According to Billionaires? - Insider Monkey
Bristol-Myers Squibb Company (BMY): Among Incredibly Cheap Dividend Stock to Buy Now - Insider Monkey
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy (NYSE:MRK) - Seeking Alpha
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
Is Bristol-Myers Squibb Company (BMY) The Best Undervalued Stock to Buy According to Billionaires? - Insider Monkey
Bristol Myers Squibb Names GM for Saudi Arabia and Gulf Countries - Contract Pharma
Bristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries - The Malaysian Reserve
Our impact - Bristol Myers Squibb
Bristol Myers Squibb (BMY) Ascends But Remains Behind Market: Some Facts to Note - Yahoo Finance
Is Bristol-Myers Squibb (BMY) the Most Undervalued Biotech Stock to Invest In? - Insider Monkey
Bristol-Myers Squibb: Why I'm Still Bullish (NYSE:BMY) - Seeking Alpha
7 Most Undervalued Biotech Stocks To Invest In - Insider Monkey
Bristol-Myers Squibb Company (BMY): A Bull Case Theory - Yahoo Finance UK
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapy - Yahoo Finance
StockWatch: Will BMS–2seventy Deal Prove a Win-Win? - Genetic Engineering & Biotechnology News
Why Bristol-Myers Squibb Company (BMY) Went Down On Thursday? - Insider Monkey
Why Bristol-Myers Squibb Company (BMY) Went Down On Friday? - Yahoo Finance
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer - Benzinga
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy By Investing.com - Investing.com South Africa
European Commission expands approval for Bristol Myers Squibb’s lymphoma therapy - Investing.com
Bristol Myers Squibb’s Breyanzi gets EU nod for lymphoma treatment - Investing.com
Bristol Myers Squibb Receives Approval From The European Commission To Expand Use Of Car T Cell Therapy Breyanzi For Relapsed Or Refractory Follicular Lymphoma - Marketscreener.com
Bristol Myers Squibb to acquire 2seventy bio for USD 286 million - Medical Dialogues
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst - Benzinga
Bristol Meyers Squibb to Acquire 2seventy bio - Contract Pharma
Bristol Myers Squibb Sets Critical Q1 Earnings Date: What Investors Should Mark on Their Calendar - StockTitan
William Blair Issues Optimistic Estimate for BMY Earnings - Defense World
Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy According to Hedge Funds? - Insider Monkey
Bristol-Myers Squibb at Leerink Global Healthcare Conference: Pipeline Progress and Strategic Insights - Investing.com India
BMS $286m partner buy secures Abecma and closes chapter on bluebird - BioXconomy
Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know - Yahoo Finance
11 Best Pharma Stocks to Buy According to Hedge Funds - Insider Monkey
BMS to acquire longtime cell therapy partner 2seventy bio for $286m - Pharmaceutical Technology
Bristol Myers Squibb (BMY) Shares Cross 4% Yield Mark - Nasdaq
Bristol Myers Squibb Acquires 2seventy bio for $286 Million - Lawyer Monthly Magazine
Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc. for approximately $280 million. - Marketscreener.com
Bristol-Myers Squibb Company agreed to acquire 2seventy bio, Inc.. -March 10, 2025 - Marketscreener.com
Eaton's Bold Acquisition Moves Into Data Centers - Finimize
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M - BioPharma Dive
Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million - Reuters
In buying cell therapy partner 2seventy bio for $286M, BMS takes full control of Abecma - FiercePharma
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal - MSN
Bristol Myers Squibb's Bold Move: Acquiring 2seventy Bio - Finimize
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):